Patients with ARDs who received RTX demonstrated impaired humoral responses to RZV, compared with healthy controls and ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

November 2024: It is announced that work is now expected to begin in January 2025. February 2025: Bangor Marine's Aran Blackbourne says that "outstanding legal issues" mean the expected start date for ...

The Company is working to expand the Phase III clinical study indication to include the treatment of respiratory distress that manifests from any cause, including acute respiratory distress ...

In June 2024, Edesa Biotech, Inc. (NASDAQ:EDSA) announced that EB05 (paridiprubart) was selected by the Biomedical Advanced Research and Development Authority (BARDA) for testing in a U.S ...

In addition to the ongoing BARDA-funded study, Edesa is conducting a separate Phase 3 trial of paridiprubart in Canada and the U.S. for ARDS patients with SARS-CoV-2 infection.

Additionally, the treatment showed support for strong Tie2 activation. AV-001 is currently recruiting patients for a Phase IIa trial as an ARDS treatment in pneumonia. 1 “Vasomune is focused on the ...

aDepartments of Emergency Medicine and Anesthesia, University of California, San Francisco, CA, USA bDepartments of Medicine and Anesthesia and the Cardiovascular Research Institute, University of ...